Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - January 22, 2025 604 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KATHERINE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Women Under 35 More Likely to Have Their Breast Cancer Spread November 4, 2021 Παρακολούθηση και Φροντίδα January 14, 2019 Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... July 9, 2021 Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... August 5, 2021 Load more HOT NEWS Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment Is CBD Safe for People With Cancer? PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer Targeting Inflammation Emerges as a Strategy for Treating Cancer
